Idogen AB
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment wi… Read more
Idogen AB (IDOGEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2023: -3.808x
Based on the latest financial reports, Idogen AB (IDOGEN) has a cash flow conversion efficiency ratio of -3.808x as of March 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.74 Million) by net assets (Skr2.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Idogen AB - Cash Flow Conversion Efficiency Trend (2014–2022)
This chart illustrates how Idogen AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Idogen AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Idogen AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ELEGANCE OPT.INT.HO.HD-10
F:5HW
|
N/A |
|
Argent
JSE:ART
|
0.099x |
|
Advanced Health Intelligence Ltd.
OTCGREY:MYZQF
|
0.476x |
|
Hempco Food and Fiber Inc
V:HEMP
|
-0.252x |
|
MicroStrategy Incorporated Variable Rate Series A Perpetual Stretch Preferred Stock
NASDAQ:STRC
|
0.000x |
|
International Prospect Ventures Ltd
PINK:URANF
|
-0.395x |
|
CKALF
PINK:CKALF
|
N/A |
|
Strive, Inc. Variable Rate Series A Perpetual Preferred Stock
NYSE:SATA
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Idogen AB (2014–2022)
The table below shows the annual cash flow conversion efficiency of Idogen AB from 2014 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | Skr3.61 Million | Skr-50.70 Million | -14.037x | -283.75% |
| 2021-12-31 | Skr10.99 Million | Skr-40.19 Million | -3.658x | -429.15% |
| 2020-12-31 | Skr40.62 Million | Skr-28.08 Million | -0.691x | +63.77% |
| 2019-12-31 | Skr18.33 Million | Skr-34.97 Million | -1.908x | -836.78% |
| 2018-12-31 | Skr51.02 Million | Skr-10.39 Million | -0.204x | +59.18% |
| 2017-12-31 | Skr39.89 Million | Skr-19.91 Million | -0.499x | +18.64% |
| 2016-12-31 | Skr18.60 Million | Skr-11.41 Million | -0.613x | +20.85% |
| 2015-12-31 | Skr12.17 Million | Skr-9.43 Million | -0.775x | -56.14% |
| 2014-12-31 | Skr3.45 Million | Skr-1.71 Million | -0.496x | -- |